Compound 21 (C21) is the only AT2R agonist used in clinical trials for idiopathic pulmonary fibrosis and COVID-19 [61,62], but not for heart disease, and there are no reports that show C21 increases Agtr2 gene expression. This evidence concerns the gene AGTR2 and pulmonary fibrosis.